Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Kimberly A, Risma"'
Autor:
Zhao-Hua Zhou, Margaret M. Cortese, Jia-Long Fang, Robert Wood, Donna S. Hummell, Kimberly A. Risma, Allison E. Norton, Mark KuKuruga, Susan Kirshner, Ronald L. Rabin, Cyrus Agarabi, Mary A. Staat, Natasha Halasa, Russell E. Ware, Anna Stahl, Maureen McMahon, Peter Browning, Panagiotis Maniatis, Shanna Bolcen, Kathryn M. Edwards, John R. Su, Sai Dharmarajan, Richard Forshee, Karen R. Broder, Steven Anderson, Steven Kozlowski
BackgroundThe mechanism for anaphylaxis following mRNA COVID-19 vaccination has been widely debated; understanding this serious adverse event is important for future vaccines of similar design. A mechanism proposed is type I hypersensitivity (i.e., I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ff339813a34daee1822c1fe92408594
https://doi.org/10.1101/2023.04.11.23288372
https://doi.org/10.1101/2023.04.11.23288372
Autor:
Lynda C. Schneider, Ronna L. Campbell, Yin Zhang, Amal Assa'ad, Hugh A. Sampson, David B.K. Golden, Kimberly A. Risma, Jonathan M. Spergel, Rakesh D. Mistry, Paul Turner, Susan A. Rudders, Kenneth A. Michelson, Carlos A. Camargo, Marcus Shaker, Brad Sobolewski, Julie Wang, David Schnadower, Peter Capucilli, Mark I. Neuman, Mariana Castells, David C. Brousseau, John K. Witry, Timothy E. Dribin, David Vyles, Michael Pistiner, Dianne E. Campbell, Margitta Worm, Juhee Lee
Publikováno v:
J Allergy Clin Immunol
Background Despite a better understanding of the epidemiology, pathogenesis, and management of patients with anaphylaxis, there remain knowledge gaps. Enumerating and prioritizing these gaps would allow limited scientific resources to be directed mor
Autor:
Kimberly A. Risma
Publikováno v:
Current Opinion in Pediatrics
Purpose of review A known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine is the only contraindication to coronavirus disease 2019 (COVID-19) mRNA vaccination. It is important for pediatricians to understand
Publikováno v:
Annals of Allergy, Asthma & Immunology. 127:264-266
Autor:
Rui Su, Rebecca A. Marsh, Lei Dong, Vanessa Gadoury-Levesque, Jianjun Chen, Kejian Zhang, Kimberly A. Risma, Miao Sun
Publikováno v:
Blood Adv
This article explores the distribution and mutation spectrum of potential disease-causing genetic variants in hemophagocytic lymphohistiocytosis (HLH)–associated genes observed in a large tertiary clinical referral laboratory. Samples from 1892 pat
Autor:
Katharine M. Guarnieri, Susan S. Xie, Joshua D. Courter, Chunyan Liu, Richard M. Ruddy, Kimberly A. Risma
Publikováno v:
The Journal of Allergy and Clinical Immunology: In Practice. 10:2951-2957.e3
Amoxicillin-associated reactions (AARs) in children presenting as rashes are common, and recent data suggest that90% tolerate amoxicillin on re-exposure. However, additional data would help pediatricians and allergists gain confidence in referring an
Autor:
Susan S. Xie, Katharine M. Guarnieri, Joshua D. Courter, Chunyan Liu, Richard M. Ruddy, Kimberly A. Risma
Publikováno v:
The Journal of Allergy and Clinical Immunology: In Practice. 10:2958-2966.e3
Autor:
Rebecca A. Marsh, Kimberly A. Risma
Publikováno v:
The Journal of Allergy and Clinical Immunology: In Practice. 7:824-832
Hemophagocytic lymphohistiocytosis (HLH) is an overwhelming clinical syndrome associated with extreme immune activation. Familial HLH is caused by autosomal-recessive inheritance of gene mutations that cripple lymphocyte cytotoxicity. X-linked lympho
Autor:
Robert A. Wood, Amy P. Stallings, Frederic F. Little, Donna S. Hummell, Joshua D. Milner, Allison E. Norton, Kathryn M. Edwards, Kimberly A. Risma
Publikováno v:
The Journal of Allergy and Clinical Immunology
Anaphylaxis to vaccines is historically a rare event. The coronavirus disease 2019 pandemic drove the need for rapid vaccine production applying a novel antigen delivery system: messenger RNA vaccines packaged in lipid nanoparticles. Unexpectedly, pu
Publikováno v:
The Journal of Allergy and Clinical Immunology: In Practice. 10:683-691.e1
Recurrent and life-threatening respiratory infections are nearly universal in patients with primary immunodeficiency diseases (PIDD). Early recognition, aggressive treatment, and prophylaxis with antimicrobials and immunoglobulin replacement have bee